Poor-risk germ cell tumors: Recent developments Journal Article
| Authors: | Dodd, P. M.; Motzer, R. J.; Bajorin, D. F. |
| Article Title: | Poor-risk germ cell tumors: Recent developments |
| Abstract: | Standard therapy for patients with poor-risk germ cell tumours remains four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy, which cures approximately 50% of this patient population. Randomized trials of conventional-dose chemotherapy have failed to identify a regimen with superior efficacy to BEP. Preliminary data suggesting efficacy for high-dose chemotherapy with stem cell or autologous bone marrow transplantation as initial therapy for poor-risk patients. The recently developed International Germ Cell Concensus Classification provides a standard method for determining poor-risk status and should be uniformly applied for both clinical decision making and risk assignment in clinical trials. |
| Keywords: | review; cisplatin; drug efficacy; antineoplastic agents; paclitaxel; drug megadose; antineoplastic agent; etoposide; drug administration schedule; tumor markers, biological; risk factors; tumor marker; ifosfamide; risk assessment; risk; testicular neoplasms; bleomycin; cancer classification; decision making; germ cell tumor; seminoma; non seminomatous germinoma; germinoma; humans; prognosis; human; male; priority journal |
| Journal Title: | Urologic Clinics of North America |
| Volume: | 25 |
| Issue: | 3 |
| ISSN: | 0094-0143 |
| Publisher: | W.B. Saunders Co-Elsevier Inc. |
| Date Published: | 1998-08-01 |
| Start Page: | 485 |
| End Page: | 493 |
| Language: | English |
| PUBMED: | 9728218 |
| PROVIDER: | scopus |
| DOI: | 10.1016/s0094-0143(05)70038-0 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 12 December 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work